Guzelj, S.; Šišić, M.; Bizjak, Š.; Frkanec, L.; Frkanec, R.; Jakopin, Ž.
Lipidation of NOD2 Agonists with Adamantane and Stearoyl Moieties Differentially Regulates Their In Vivo Adjuvant Activity. Pharmaceutics 2022, 14, 2755.
https://doi.org/10.3390/pharmaceutics14122755
AMA Style
Guzelj S, Šišić M, Bizjak Š, Frkanec L, Frkanec R, Jakopin Ž.
Lipidation of NOD2 Agonists with Adamantane and Stearoyl Moieties Differentially Regulates Their In Vivo Adjuvant Activity. Pharmaceutics. 2022; 14(12):2755.
https://doi.org/10.3390/pharmaceutics14122755
Chicago/Turabian Style
Guzelj, Samo, Marcela Šišić, Špela Bizjak, Leo Frkanec, Ruža Frkanec, and Žiga Jakopin.
2022. "Lipidation of NOD2 Agonists with Adamantane and Stearoyl Moieties Differentially Regulates Their In Vivo Adjuvant Activity" Pharmaceutics 14, no. 12: 2755.
https://doi.org/10.3390/pharmaceutics14122755
APA Style
Guzelj, S., Šišić, M., Bizjak, Š., Frkanec, L., Frkanec, R., & Jakopin, Ž.
(2022). Lipidation of NOD2 Agonists with Adamantane and Stearoyl Moieties Differentially Regulates Their In Vivo Adjuvant Activity. Pharmaceutics, 14(12), 2755.
https://doi.org/10.3390/pharmaceutics14122755